Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 9/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 9/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1531548 | 1.00 | GRN (0.46) | GRNSORT1MAPTMEN1KMT2A | |
| SCHEMBL1531587 | 0.89 | GRM4 (0.41) | GRNSORT1MAPTMEN1KMT2A | |
| SCHEMBL1531584 | 0.89 | GRM4 (0.41) | GRNSORT1MAPTMEN1KMT2A | |
| SCHEMBL1531707 | 0.84 | L3MBTL1 (0.38) | GRNSORT1MAPTMEN1KMT2A | |
| SCHEMBL1531484 | 0.83 | MAPK1 (0.56) | MAPTMEN1KMT2AMAPK1RAB9A | |
| SCHEMBL1531481 | 0.83 | MAPK1 (0.56) | MAPTMEN1KMT2AMAPK1RAB9A | |
| SCHEMBL8785420 | 0.82 | GRN (0.44) | GRNSORT1MAPTMEN1KMT2A | |
| SCHEMBL11195208 | 0.82 | HTT (0.45) | GRNSORT1MAPTMEN1KMT2A | |
| SCHEMBL25042405 | 0.79 | GRN (0.42) | GRNSORT1MAPTMEN1KMT2A | |
| SCHEMBL9962440 | 0.79 | RAB9A (0.49) | GRNSORT1MEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029359-B2 | Heteroaryl Btk inhibitors | BIOGEN IDEC MA, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2485589-A1 | HETEROARYL BTK INHIBITORS | Biogen Idec MA Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20120157442-A1 | HETEROARYL BTK INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011029043-A1 | HETEROARYL BTK INHIBITORS | BIOGEN IDEC MA INC. (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157442-A1 | HETEROARYL BTK INHIBITORS | BTK, LYN, SYK | GRN 4415/4885SORT1 4585/4885MAPT 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.